Autoinjectors and related methods of use

Abstract

An injection device includes: a carrier; a needle; a driver coupled to the needle, the driver slidable relative to the carrier between a retracted configuration and a deployed configuration; a shuttle member configured to move the driver between the retracted configuration and the deployed configuration; and a stopper configured to move from a first configuration to a second configuration, where the stopper is configured to hold the driver in the deployed configuration, and movement of the stop from the first configuration to the second configuration allows the shuttle to move the driver from the deployed configuration to the retracted configuration.

Description

[0001] This application is a divisional application of application number 201880027244.5, application date 2018.5.4, named “Automatic syringe and related methods of use”, and a divisional application submitted on 2022.5.17 (application number 202210535418.7, named “Automatic syringe and related methods of use”).

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This patent application claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Patent Application No. 62 / 502,278, filed May 5, 2017, the entire contents of which are incorporated herein by reference. Technical Field

[0004] The present disclosure relates to an autoinjector and related methods of use. Background Art

[0005] In various available automatic injectors, once activated by the user, the needle is deployed and the fluid is delivered from the needle into the user's body. After completing the fluid delivery, the needle can be retracted for the purpose of user comfort, needle safety and product positive perception. However, many automatic injectors use separate springs or motors to perform the injection and needle removal steps. In addition, such injection assemblies usually require separate user operations to insert and remove both needles. Summary of the invention

[0006] In one aspect, the present disclosure relates to an injection device. The injection device includes: a carriage; a needle; a driver coupled to the needle, the driver slidable relative to the carriage between a retracted configuration and a deployed configuration; a shuttle configured to move the driver between the retracted configuration and the deployed configuration; and a stop configured to move from a first configuration to a second configuration, wherein the stop is configured to hold the driver in the deployed configuration, and movement of the stop from the first configuration to the second configuration allows the shuttle to move the driver from the deployed configuration to the retracted configuration.

[0007] The shuttle is movable from a first position to a second position, and from the second position to a third position, wherein when the shuttle is in the first position, the driver is in the retracted configuration; when the shuttle is in the second position, the driver is in the deployed configuration; and when the shuttle is in the third position, the driver is in the retracted configuration. The first position is different from the third position. The shuttle moves along an axis in one direction to move from the first position to the second position, and from the second position to the third position. The shuttle is configured to move in only one direction. The injection device also includes a deployment gear coupled to the carriage and a retraction gear coupled to the carriage, wherein the driver is coupled to the deployment gear and the retraction gear, and the shuttle includes a rack gear configured to engage the deployment gear and the retraction gear, wherein direct engagement of the rack gear with the deployment gear causes the driver to move from the retracted configuration to the deployed configuration, and direct engagement of the rack gear with the retraction gear causes the driver to move from the deployed configuration to the retracted configuration. The rack gear is in direct contact with only one of the deployment gear and the retraction gear at any time. The rack gear is configured to drive the rotation of the deployment gear in a first direction so that the driver moves from the retraction configuration to the deployment configuration, and drives the rotation of the retraction gear in the first direction so that the driver moves from the deployment configuration to the retraction configuration. The driver includes a first rack and a second rack, wherein the first rack is configured to engage the deployment gear and the second rack is configured to engage the retraction gear. The first rack and the second rack are located on opposite sides of the driver. The shuttle is configured to move along a first axis, the driver is configured to move along a second axis, and the first axis and the second axis are perpendicular to each other. Prior to activation, the driver contacts an obstacle and is prevented from moving out of the retraction configuration by the obstacle. The injection device also includes a housing enclosing the bracket, wherein the obstacle is integral with the housing. Movement of the bracket relative to the housing causes the driver to move without contacting the obstacle, thereby allowing the driver to move from the retraction configuration to the deployment configuration. The injection device further includes a resilient member coupled to the shuttle, wherein after the driver moves out of contact with the obstacle, the resilient member is configured to expand from a first compressed state to a second compressed state to move the shuttle from the first position to the second position. After the stopper moves from the first configuration to the second configuration, the resilient member is configured to expand from the second compressed state to a rest state to move the shuttle from the second position to the third position.

[0008] In another aspect, the present disclosure relates to an injection device comprising: a carriage having a stopper, wherein the stopper has a first end fixed to the rest of the carriage and a free second end; a first gear coupled to the carriage; a needle; a driver coupled to the carriage, the driver being slidable relative to the carriage between a retracted configuration and a deployed configuration; a shuttle, the shuttle comprising a rack gear configured to drive rotation of the first gear, wherein rotation of the first gear causes the driver to move from the retracted configuration to the deployed configuration, wherein the free second end of the stopper is configured to at least temporarily prevent movement of the shuttle when the driver is in the deployed configuration.

[0009] The injection device also includes a second gear coupled to the bracket, wherein the stopper flexes about the fixed first end while the free second end contacts the shuttle, causing the shuttle to slide relative to the stopper and drive rotation of the second gear, wherein the rotation of the second gear moves the driver from the deployed configuration to the retracted configuration.

[0010] In another aspect, the present disclosure relates to an injection device comprising: a needle movable between a retracted configuration and a deployed configuration; a vial configured to be in fluid communication with the needle; a piston configured to move within the vial; a motor configured to drive the piston; and a controller coupled to the motor, wherein the controller is configured to receive an indication that the injection device is positioned for contact with a user, and upon receiving the indication, send a signal to the motor to drive the piston in a first direction to connect the needle to the vial fluid and move the needle from the retracted configuration to the deployed configuration, and after receiving the indication, no user intervention is required, and upon sending the signal to drive the motor in the first direction, automatically send a signal to the motor to drive the piston in a second direction to move the needle from the deployed configuration to the retracted configuration.

[0011] The injection device also includes a housing enclosing the vial, the piston, the motor, the controller, and the needle when the needle is in the retracted configuration, wherein the needle extends out of the housing in the deployed configuration. The injection device may include a cover or shield that contains a distal-most portion of the needle in the retracted configuration. The injection device may include an audio module, a visual module, and a tactile module, each of which is coupled to the controller and configured to provide feedback to a user of the injection device. The injection device may include a top that seals the opening of the vial, the top including a portion comprising a rubber material that is permeable to the disinfectant, wherein the needle includes a proximal-most portion configured to couple with the vial, and the proximal-most portion of the needle is disposed within the portion formed by the rubber material before the needle and the vial are in fluid communication with each other. The injection device may include a cantilever coupled to the controller and movable by the needle, wherein when the needle is in the retracted configuration, the cantilever forms part of an open circuit that signals to the controller that the needle is in the retracted configuration, and when the needle is in the deployed configuration, the cantilever forms part of a closed circuit that signals to the controller that the needle is in the deployed configuration. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate various examples and, together with the description, serve to explain the principles of the disclosed examples and embodiments.

[0013] Various aspects of the present disclosure may be implemented in conjunction with the embodiments shown in the accompanying drawings. These drawings illustrate different aspects of the present disclosure, and where appropriate, reference numerals illustrating similar structures, components, materials, and / or elements in different drawings are similarly labeled. It should be understood that various combinations of structures, components, and / or elements other than those specifically shown are contemplated and within the scope of the present disclosure.

[0014] In addition, many embodiments are described and illustrated herein. The present disclosure is not limited to any single aspect or embodiment thereof, nor is it limited to any combination and / or arrangement of such aspects and / or embodiments. In addition, each aspect and / or embodiment of the present disclosure may be used alone or in combination with one or more other aspects and / or embodiments of the present disclosure. For the sake of brevity, certain arrangements and combinations are not discussed and / or illustrated separately herein. It is noteworthy that an embodiment or implementation described herein as “exemplary” should not be interpreted as preferred or advantageous, for example, relative to other embodiments or implementations; on the contrary, it is intended to reflect or indicate that one or more embodiments are “exemplary” embodiments.

[0015] Figure 1 is a perspective view of an automatic injector according to an example of the present disclosure.

[0016] Figure 2 yes Figure 1 Bottom view of the auto-injector.

[0017] Figure 3 yes Figure 1 A side view of an autoinjector showing an activation switch extending away from the tissue-facing surface.

[0018] Figure 4 yes Figure 1 Exploded view of the auto-injector.

[0019] Figure 4A yes Figure 1 Schematic diagram of the control system of the automatic injector.

[0020] Figure 4B is an exploded view of an autoinjector according to the present disclosure.

[0021] Figure 4C is a perspective view of a portion of a housing and an electronic board according to aspects of the present disclosure.

[0022] Figure 5 It is an exploded view of the needle mechanism.

[0023] Figure 6 yes Figure 5 A perspective view of the needle mechanism in a first position.

[0024] Figures 7 to 11 yes Figure 5 Side view of the needle mechanism.

[0025] Fig.12 yes Figure 1 A side cross-sectional view of a portion of an automatic injector.

[0026] Fig.13 and Fig.14 is a side cross-sectional view of the piercing mechanism.

[0027] Fig.14A is a cross-sectional view of a cap for an alternative piercing mechanism.

[0028] Fig.15 is a side view of the pin inserted into the switch.

[0029] Fig.16 is a flow chart of an exemplary method according to the present disclosure.

[0030] Figures 17 to 23 A needle mechanism according to other examples of the present disclosure is shown.

[0031] Fig.24 yes Figure 1 Cross-sectional view of an auto-injector and needle shield.

[0032] Fig.25 yes Fig.24 A magnified view of a portion of .

[0033] Likewise, many embodiments are described and illustrated herein. The present disclosure is not limited to any single aspect or embodiment thereof, nor is it limited to any combination and / or arrangement of such aspects and / or embodiments. Each aspect and / or its embodiment of the present disclosure may be used alone, or in combination with one or more other aspects and / or its embodiments of the present disclosure. For the sake of brevity, many of these combinations and arrangements are not discussed separately herein.

[0034] It is worth noting that, in order to simplify and clarify the description, certain aspects of the drawings depict the general structure and / or construction of various embodiments. Descriptions and details of well-known features and technologies may be omitted to avoid unnecessarily obscuring other features. The elements in the drawings are not necessarily drawn to scale; the dimensions of some features may be exaggerated relative to other elements to improve the understanding of the exemplary embodiments. For example, it should be understood by those of ordinary skill in the art that the cross-sectional views are not drawn to scale and should not be considered to represent the proportional relationship between different parts. The cross-sectional views are provided to help illustrate the various components of the depicted components and show their positioning relative to each other. DETAILED DESCRIPTION

[0035] Reference will now be made in detail to examples of the present disclosure, which are illustrated in the accompanying drawings. Wherever possible, the same reference numerals will be used throughout the drawings to refer to the same or like parts. In the following discussion, relevant terms such as "about," "substantially," "approximately," etc. are used to indicate possible variations of ±10% of the stated values.

[0036] As described above, existing automatic injectors typically require multiple user interactions for self-administration, including, for example, a separate user interaction for deploying the needle and for subsequently retracting the needle after drug delivery. These additional steps can increase the complexity of self-administration of the drug, introduce user errors, and cause user discomfort. Therefore, the present disclosure relates to various embodiments of injection devices (e.g., automatic injectors) that simplify user self-administration of drugs or other therapeutic agents. Specifically, according to certain embodiments, when the needle is inserted subcutaneously into the user's body, the automatic injector may not require any additional user interaction to withdraw the needle. Therefore, the automatic injector of the present disclosure is simplified to help prevent misuse or user errors.

[0037] Overall system

[0038] Figures 1 to 4An example of such an autoinjector 2 is shown. The autoinjector 2 may include a housing 3 having a tissue engaging (eg, bottom) surface 4 through which a needle may be inserted. Figure 2 ) through the tissue engaging surface 4 for deployment and retraction. Activation switch 1409 ( Figure 2 ) may be disposed on the tissue engaging surface 4 and may be configured to activate the auto-injector 2, or otherwise place the auto-injector 2 in a "ready" mode. Touch sensor 1410 ( Figure 2 ) may also be disposed on the tissue engaging surface 4 and may be configured to assist the controller of the auto-injector 2 in determining whether the auto-injector 2 is disposed on the user's skin (indicating that the auto-injector should fire or otherwise deploy the needle), or whether the activation switch 1409 has been improperly triggered (indicating that the operation of the auto-injector 2 should be stopped). The activation switch 1409 and the touch sensor 1410 will be described below with reference to Figure 4A The connection port 13 may also be disposed on the tissue engaging surface 4 to facilitate programming of the automatic injector 2. The housing 3 may include a transparent window 50 to enable an observer to view one or more displays or LEDs 52 disposed within the housing 3 (see FIG. Figure 4B ), and may also include a plurality of openings 51, which are configured to facilitate the travel of sound generated (through, for example, a speaker) within the housing 3. The LEDs 52 may be arranged in a ring form or in any other suitable form. The automatic injector 2 may have any suitable size suitable for being portable and self-attached by a user. In one example, the automatic injector 2 may have a length of about 2.98 inches, a width of about 2.07 inches, and a height of about 1.07 inches. However, other suitable values ​​may also be utilized, including, for example, a length of about 0.5 inches to about 5.0 inches, a width of about 0.5 inches to about 3.0 inches, and a height from 0.5 inches to about 2.0 inches.

[0039] The autoinjector 2 can be oriented about a longitudinal axis 40 (e.g., X-axis), a transverse axis 42 (e.g., Y-axis) substantially perpendicular to the longitudinal axis 40, and a vertical axis 44 (e.g., Z-axis) substantially perpendicular to both the longitudinal axis 40 and the transverse axis 42.

[0040] Adhesive patch 12 can be coupled to tissue engagement surface 4 to help autoinjector 2 be fixed to user's body (e.g., skin). Adhesive patch 12 can be formed by fabric or any other suitable material, and can include adhesive. Adhesive can be water-based or solvent-based adhesive, or can be, for example, hot melt adhesive. Suitable adhesive also includes acrylic, dextrin and urethane adhesives and natural elastomers and synthetic elastomers. In some instances, the adhesive provided on patch 12 can be activated when in contact with user's skin. In another example again, patch 12 can include nonwoven polyester substrate and acrylic or silicone adhesive. Patch 12 can be joined to housing 3 by, for example, double-sided adhesive or by other mechanisms such as ultrasonic welding. The length dimension of patch 12 can be greater than the width of autoinjector 2.

[0041] Needle Mechanism

[0042] refer to Figures 5 to 11 The needle mechanism 20 includes a bracket 202, which can be in a first position ( Figure 6 ) and the second position ( Figure 7 ) between the housing 3 and the housing 3. The needle mechanism 20 may also include a fluid conduit 300 mounted to the bracket 202, and the fluid conduit 300 may be deployed into the user's body and retracted by the driver 320. The shuttle 340 (e.g., a shuttle actuator) may be configured to move the driver 320 via a deployment gear 360 and a retraction gear 362. The shuttle 340 may be coupled to a resilient member (e.g., a spring 370). The cap 380 ( Figure 5 ) can be coupled to the bracket 202 to enclose the various components of the needle mechanism 20.

[0043] refer to Figure 5 , the fluid conduit 300 may extend from a first end 302 to a second end 304. The first end 302 may include a needle 306 configured to be injected into a user. The needle 306 may include a sharp and / or beveled tip and may extend generally along the axis 44 or parallel to the axis 44. The second end 304 may include a needle 308 that is substantially similar to the needle 306, but which may be positioned within the auto-injector 2 to penetrate the vial 1302 (at Fig.1344 and described in further detail below) to access the drug to be injected into the user's body. The fluid conduit 300 may include an intermediate section 310, which includes a portion extending along or parallel to the axis 40, and a second portion extending along or parallel to the axis 40. The first and second portions of the intermediate section 310 may be engaged in a coil 312, which facilitates flexion of the fluid conduit 300 and movement of the needle 306 along the axis 44 during deployment of the needle 306 into the user's body and during retraction from the user's body. Although the coil 312 is shown, any other suitable shape is also contemplated, such as a serpentine, curved, or other shape that enables flexion of the fluid conduit 300. The coil 312 or a similar structure may act as a cantilever when the needle 306 is deployed and / or retracted. The coil 312 may also bias the fluid conduit 300 to Figure 5 Once needle 308 penetrates vial 1302 and establishes fluid communication with vial 1302 (see, e.g., Fig.14 ), the drug can travel from the vial 1302 through the needle 308, the intermediate section 310 and the needle 306 (piercing through the user's skin), and enter the user's body. In some examples, the fluid conduit 300 may include only metal or metal alloys. In other examples, the fluid conduit 300 may include any other suitable material, such as, for example, a polymer, etc. The needle 308 and the intermediate section 310 may be defined as a 22 gauge or 23 gauge thin wall needle, while the needle 306 may be a 27 gauge needle. Other sizes of needles ranging from, for example, 6 gauge to 34 gauge may also be appropriately utilized. The fluid conduit 300 can reduce the amount of material that comes into contact with the drug, reduce joints and assembly steps, and require less sterilization than conventional devices.

[0044] The carriage 202 may be formed of plastic (e.g., injection molded plastic), metal, metal alloy, etc., and may include a flange 204 having an opening 206, and posts 210 and 212. The carriage 202 may also include an opening 216 through which a needle or other fluid conduit may be deployed. The opening 216 may be a slot recessed from an end face of the carriage 202, or, in an alternative embodiment, the entire perimeter of the opening 216 may be defined by the material of the carriage 202. The carriage 202 also includes a driver path 218. The driver path 218 may be a slot in the carriage 202 extending along the axis 44 or extending parallel to the axis 44. The driver path 218 may be configured to receive a protrusion of the driver 320, such as, for example, the protrusion 330 discussed in further detail below. The carriage 202 may also include a shuttle path 220 along which a shuttle 340 may move, as described in further detail below.

[0045] The bracket 202 may also include a stopper 240 configured to engage the shuttle 340. The stopper 240 may be a Figure 8 ) and free end 242 ( Figure 8 ) cantilever. The stopper 240 may include an inclined ramp 243 ( Fig. 9 and Fig.12 ), when the slope is 1500 (reference Fig.12 When the stopper 240 is engaged or pushed by the fixed end 241, the stopper 240 is deflected about the fixed end 241. In the first position, the free end 242 can block or otherwise hinder the movement of the shuttle 340, and in the second configuration, the free end 242 can allow the movement of the shuttle 340. The relationship between the stopper 240 and the shuttle 340 will be discussed in further detail later in this application.

[0046] The driver 320 includes two racks 322 and a rack 324 (eg, Figure 8 320 may include an inner cavity 326 (or a track, groove or other suitable structure) ( Figure 5 ), the inner cavity 326 is configured to receive the needle 306 of the fluid conduit 300. The driver 320 may also include a protrusion 330 ( Figure 6 and Figure 7 ), the protrusion 330 is configured to slide within the drive path 218 of the bracket 202. The protrusion 330 may include a hook-like configuration that can "grab" the obstacle 600, as described in further detail below.

[0047] Continue to refer Figure 5 , the shuttle 340 may include a rack 342 configured to engage with the gear 360 and the gear 362. The shuttle 340 may also include an end face 344 and a groove 346 extending along the length of the shuttle 340 in the same direction as the rack 342. The slot 348 ( Fig. 9 ) can extend along the length of the groove 346. The narrow groove 348 can extend through the middle of the groove 346 and can extend along the entire groove 346 or substantially the entire groove 346.

[0048] The shuttle 340 can move along the track 220 from a first starting position ( Figure 8 ) moves to the second intermediate position ( Fig. 9 and Fig.10 ), and moves from the second position to the third final position (at Fig.11360 and the retraction gear 362. In some instances, the rack 342 is engaged with at most one of the deployment gear 360 and the retraction gear 362 at any given time. In some instances, such as when the rack 342 is longitudinally disposed between the deployment gear 360 and the retraction gear 362, the rack 342 is not engaged with either the deployment gear 360 or the retraction gear 362. The shuttle 340 may be configured to move only along one axis (e.g., axis 40) and only in one direction along one axis. The force required to move the shuttle 340 along the track 220 may be provided by the extension of the spring 370. The spring 370 may be compressed from a stationary state, and the extension of the spring 370 may cause the shuttle 340 to move along the track 220 through the series of positions / configurations set forth above. At various positions of the shuttle 340 , different features of the autoinjector 2 may directly or indirectly block movement of the shuttle 340 .

[0049] like Figure 8 As shown, the first position of the shuttle 340 may correspond to an unused, undeployed and / or new state of the automatic injector 2. In this first position, the driver 320 may be in an undeployed state. By positioning an obstacle 600 ( Figure 6 ) holds the shuttle 340 in the first position. The barrier 600, which may be a shelf of the housing 3, or other suitable blocking device, may prevent movement of the driver 320 by engaging and / or retaining the protrusion 330. Thus, because the driver 320, the deployment gear 360, and the rack 342 are coupled to one another, blocking the driver 320 also prevents movement of the shuttle 340. The shuttle 340 may be moved from the first position to the second position by moving the barrier 600 relative to the bracket 202 (or vice versa). In one example, the bracket 202 is moved (e.g., in Figure 6 , while obstacle 600 remains stationary.

[0050] When there is no obstacle 600 ( Figure 7 ), spring 370 can extend and move shuttle 340 along track 220. This linear movement of shuttle 340 can rotate deployment gear 360 counterclockwise (or clockwise in other examples) via rack 342, and the rotation of deployment gear 360 can move driver 320 downward along axis 44 via rack 322 of driver 320. This downward movement of driver 320 can cause needle 306 to pierce through the user's skin. In some examples, driver 320 can be configured to move only along axis 44 relative to bracket 202.

[0051] The shuttle 340 can be moved by the extension of the spring 370 until its end surface 344 abuts the free end 242 of the stopper 240, so that the shuttle 340 is kept in the Fig. 9 and Fig.10 The second position is shown. At this point, the free end 242 prevents further extension of the spring 370 and further movement of the shuttle 340 along the track 220. In this second position, the fluid conduit 300 can be deployed in the user's body and the fluid from the vial 1302 can be injected into the user's body through the needle 306. In addition, when the shuttle 340 is in the second position, the rack 342 can engage the deployment gear 360 to maintain the needle 306 in the deployed configuration. The shuttle 340 can be moved from the second position to the third position by flexing the stop 240 about its fixed end 241. Further details of this flexure are described below with reference to Figure 12 to Figure 14 The flexing of the stop 240 may allow the spring 370 to continue to expand, thereby further pushing the shuttle 340 along the track 220. In some examples, when the shuttle 340 moves from the second position to the third position, the stop 240 may be received by and / or within the groove 346 of the shuttle 340, and the ramp 243 may slide within the slot 348.

[0052] The movement of the shuttle 340 from the second position to the third position can correspond to the retraction of the needle 306 from the user's body into the housing 3. In particular, when the deployment gear 360 rotates, the rack 342 can engage with the retraction gear 362 and rotate the retraction gear 362 in the same direction (e.g., counterclockwise or clockwise). The rotation of the retraction gear 362 can push the driver 320 back to the retracted position through the rack 324. When the end surface 344 of the shuttle 340 engages with the wall of the bracket 202, when the free end 242 of the stopper 240 reaches the end of the groove 346, and / or when the spring 370 reaches a static state, the shuttle 340 can reach the third position, in which the driver 320 is fully retracted.

[0053] In some embodiments, once the driver 320 is moved back from the deployed state to the retracted state, it can be prevented from moving out of the retracted state. Thus, the needle 306 will be prevented from being redeployed into the user's body. In this configuration, the automatic injector 2 can be a disposable device (e.g., discarded after completing an injection). In other embodiments, the automatic injector 2 can be reset and reused. In addition, in some examples, the deployment gear 360 and the retraction gear 362 can be the only rotating gears disposed within the automatic injector 2.

[0054] Piercing Systems and Sterile Connectors

[0055] Fig.13 and Fig.14Features of the piercing system 1300 of the autoinjector 2 are shown. Additional details of an exemplary piercing system can be found in U.S. Patent Application Publication No. 2016 / 0262984A1 to Arnott et al., published on September 15, 2016, the entire contents of which are incorporated herein by reference. The piercing system 1300 includes a main container, chamber, syringe, cartridge, or vial 1302 having a first end 1304 and a second end 1306. The vial 1302 may also include a cavity 1308, which opens at the first end 1304 and extends toward the second end 1306. The second end 1306 may include a neck 1310 with a cap 1312, which engages the neck 1310 to close the second end 1306. A septum 1314 can be positioned between the vial 1302 and the cap 1312 to help close the second end 1306 and allow a needle 308 (eg, a staked needle) to be inserted into the vial 1302. The cavity 1308 can be closed at the first end 1304 by a piston 1316.

[0056] In some examples, the vial 1302 may have a 5 mL capacity, but any other suitable volume (e.g., from 1 mL to 50 mL, or from 2 mL to 10 mL, or from 3 mL to 6 mL, or from 2 mL to 5 mL, or other suitable ranges) may be utilized depending on the drug to be delivered. In other examples, the vial 1302 may have a capacity greater than or equal to 1 mL, or greater than or equal to 2 mL, or greater than or equal to 3 mL, or greater than or equal to 4 mL, or greater than or equal to 5 mL. The vial 1302 may contain and store drugs for injection into the user's body, and may help maintain the sterility of the drug. The vial 1302 may have a 13 mm diameter neck, a length of 45 mm, and an inner diameter of 19.05 mm. These values ​​are merely exemplary, and other suitable sizes may be utilized as appropriate. In some examples, the vial 1302 may be formed using conventional materials and may be shorter than existing devices, which may help the automatic injector 2 remain cost-effective and miniaturized. The vial 1302 may be a shortened ISO 10 mL cartridge.

[0057] The diaphragm 1314 may include an uncoated brominated butyl material or another suitable material. The piston 1316 may include a fluoropolymer coated brominated butyl material and may also include a tapered nose 1316a to help reduce the dead volume within the vial 1302. The piston 1316 may include one or more rubber materials such as, for example, halogenated butyl (e.g., brominated butyl, chlorobutyl, fluorobutyl) and / or nitrile, among other materials.

[0058] The piercing system 1300 may also include a top 1354 positioned at the second end 1306. The top 1354 may include a base 1355 positioned on the septum 1314 and an opening of the vial 1302. The top 1354 may include a chamber 1356 extending from the base 1355 in a direction away from the piston 1316. The chamber 1356 defines a cavity 1357 and includes an opening 1358 communicating with the cavity 1357. In some embodiments, the top 1354 may be integrated with the septum 1314 (e.g., a monolithic structure or a one-piece structure). In an alternative embodiment (not shown), the top 1354 may be disposed on the fluid conduit 300 or initially assembled on the fluid conduit 300, rather than being directly mounted on / mounted with the vial 1302 and / or integrated with the septum 1314.

[0059] In the pre-start state, a portion of the fluid conduit 300, such as a needle 308, a tube, etc., may extend through the opening 1358 of the chamber 1356 and into the cavity 1357, but not through the base 1355. The opening 1358 may be preformed, or may be formed by the penetration of the needle 308 through the chamber 1356. The opening 1358 of the chamber 1356 may form a sterile sliding seal around the needle 308, so that pathogens or other contaminants are prevented from passing into the cavity 1357. The needle 308 may move relative to the top 1354 without destroying the sterile seal therebetween. The cavity 1357 may be sterile or sterilized, so that the inner surface of the cavity 1357 and the needle 308 are sterile. In another embodiment, after the needle 308 is inserted through the opening 1358 and into the cavity 1357, the cavity 1357 may be sterilized. In an alternative embodiment, instead of the top 1354, a convoluted flexible (e.g., rubber) bellows or bladder member may form the cavity 1357 and allow the vial 1302 to translate relative to the needle 308 (or vice versa). The flexible member may also seal the cavity 1354 after sterilization or form the cavity 1354 around the needle 308.

[0060] exist Fig.14AIn the alternative embodiment shown, top 1354a can be used with piercing system 1300 to replace top 1354. Top 1354a can include stopper 1356a and base 1355a positioned on the opening of vial 1302. Stopper 1356a can extend from base 1355a in a direction away from piston 1316. In the pre-start state, needle 308 can be arranged in stopper 1356a. Stopper 1356a can be a solid stopper without any holes, cavities or openings, and can be formed by a first rubber material. The first rubber material can be permeable to sterilizing gases (such as, for example, ethylene oxide or vaporized hydrogen peroxide). The first rubber material can include one or more of isoprene, ethylene propylene diene monomer (M grade) rubber (EPDM) and styrene-butadiene, etc. The permeability of the first rubber material to sterilizing gases can allow the needle 308 arranged in stopper 1356a to be sterilized before use. The stopper 1356a can be molded around the needle 308 so that the needle 308 penetrates the stopper 1356a. The impermeability of the base 1355a to the sterilizing gas can prevent contamination and / or tampering with the drug contained in the vial 1302. The base 1355a can include an impermeable rubber such as, for example, halogenated butyl (e.g., brominated butyl, chlorobutyl, fluorobutyl) and / or nitrile, among other materials.

[0061] The piston 1316 can be coupled to a translation mechanism 1366 that is configured to translate the piston 1316 and the vial 1302 in a direction toward the second end 1306. Movement of the piston 1316 toward the second end 1306 causes the piston 1316 to act on the contents (e.g., drug, medicament) within the vial 1302, which ultimately transfers force to the second end 1306 of the vial 1302, thereby causing the vial 1302 to move along the longitudinal axis 40. The translation mechanism 1366 can include a 12 mm motor with a five-stage gear reduction (360:1). The translation mechanism 1366 can have spring contacts that form an electrical connection with an associated printed circuit board (e.g., the first electronic board 1402). The motor can be configured to generate approximately 136 mN at 36 rpm. * These design parameters of the motor are merely exemplary, and other suitable motors may also be utilized.

[0062] The translation mechanism 1366 may include a screw mechanism coupled to the piston 1316, which extends axially when relatively rotated about the longitudinal axis 40. This telescopic screw may have a 100N output, a 20mm stroke, and a 7° / 45° trapezoidal thread shape with a pitch of 0.75mm. Materials for the screw mechanism may include acetal and polybutylene terephthalate. The screw mechanism may extend within the piston 1316 to reduce the dead space behind the piston 1316. Although Fig.13 and Fig.14The piston 1316 shown in the figure has longitudinally spaced threads, but in some instances, such threads may not be present. In another exemplary embodiment (not shown), the translation mechanism 1366 may include a manually engageable surface or member that is manually manipulated by a user to move the piston 1316. For example, the piercing system 1300 may include a cartridge or plunger coupled to the rear side of the piston 1316. In another exemplary embodiment (not shown), the translation mechanism 1366 may include a pneumatic or hydraulic drive member that is actuated or initiated by a user to move the piston 1316. The drive member may be in the form of, for example, an expansion bellows, an expansion bladder, an expansion diaphragm, or a sliding seal or piston. Direct pneumatic pressure or hydraulic pressure may provide the force required to move the piston 1316.

[0063] The piercing system 1300 also includes a collar 1390 coupled to or secured to the second end 1306. The collar 1390 may include a plurality of circumferentially spaced apart fingers 1392 that engage and surround the neck 1310. The collar 1390 may be secured to or otherwise coupled to the second end 1306. The collar 1390 may include a wall 1390a that extends at least partially around the neck 1310, the opening of the second end 1306, the cap 1312, the septum 1314, and / or the top 1354. The wall 1390a of the collar 1390 may be positioned radially or laterally outside of the neck 1310 and extend longitudinally beyond the neck 1310, the cap 1312, and the septum 1314.

[0064] exist Fig.13 In the illustrated pre-activated state of the piercing system 1300, the edge 1393 of the collar 1390 may engage a corresponding radially or laterally inwardly extending cam, latch, or actuation portion 1394 of a driver retaining member 1395. The retaining member 1395 may be slidable relative to the collar 1390. The collar 1390 and the retaining member 1395 may be configured such that in Fig.13 In the pre-activated state or arrangement shown, at least a portion of the cam or actuating portion 1394 of the retaining member 1395 is positioned directly behind a retaining portion 1399 of a driver 1398 that is slidable within the retaining member 1395. The wall 1391 of the driver 1398 can extend into and through the end cap portion 1396 of the retaining member 1395 and into the interior portion of the retaining member 1395, and the retaining portion 1399 of the driver 1398 can extend radially outward from the wall 1391. In some embodiments, the wall 1391 of the driver 1398 can be substantially cylindrical, and the retaining portion 1399 of the driver 1398 can be a flange extending around the end of the wall 1391.

[0065] In the pre-activated state of the piercing system 1300, a resiliently deformable biasing or resilient member 1397 may be positioned between the cap portion 1396 of the retaining member 1395 and the retaining portion 1399 of the driver 1398. The biasing member 1397 may apply a force to the driver 1398 in the pre-activated state of the piercing system 1300 that acts in a direction toward the vial 1302. The biasing member 1397 may be any member effective to apply the force in the pre-activated state and then release such force upon activation, as described below with reference to Fig.14 In some embodiments, the biasing member 1397 can be a conical spring or a leaf spring.

[0066] The needle 308 of the fluid conduit 300 can be fixed to or coupled to the driver 1398 so that the fluid conduit 300 moves with the driver 1398. In the pre-activated state of the piercing system 1300, the needle 308 can be positioned within the sterile cavity 1357, but does not pass through the base 1355 of the top 1354, the septum 1314, and / or enter the cavity 1308 of the vial 1302.

[0067] In order to make the puncture system 1300 Fig.13 The pre-activated state moves the translation mechanism 1366, which can activate the translation mechanism 1366 to move the piston 1316 toward the second end 1306 and translate the vial 1302 along the longitudinal axis 40 toward the driver 1398. Because the needle 308 is not yet in fluid communication with the vial 1302, the activation of the translation mechanism 1366 applies pressure to the fluid contained in the vial 1302, which is then applied to the vial 1302 itself. This pressure also causes the edge 1393 to push against the actuation portion 1394 and deflect the actuation portion 1394 radially outward. Without the actuation portion 1394 blocking their path, the retaining portion 1399 and the needle 308 are moved toward the vial 1302 by the extension of the biasing member 1397. The driver 1398 can be coupled to the flange 204 of the bracket 202, so that this movement of the driver 1398 toward the vial 1302 can also move the bracket 202 in the same direction. This movement corresponds to Figure 6 and Figure 7 The movement of the bracket 202 relative to the housing 3 enables the protrusion 330 to clear the obstacle 600 to allow the needle 306 to be injected.

[0068] Movement of the needle 308 toward the second end 1306 of the vial 1302 also causes the needle 308 to pierce the base 1355 of the top 1354, the septum 1314, and the cavity 1308, into fluid communication with the contents of the vial 1302. Once the needle 308 is in fluid communication with the vial 1302, further movement of the piston 1316 toward the second end 1306 pushes the fluid through the needle 308 and the remainder of the fluid conduit 300. In some embodiments, the piercing system 1300 can be configured so that after activation, no more portion of the needle 308 extends into the cavity 1308 than is already positioned within the sterile cavity 1357. This can help prevent contamination of the contents of the vial 1302 by non-sterile portions of the needle 308.

[0069] The biasing member 1397 can be configured to expand to cause the fluid conduit 300 to pierce the top 1354 and / or the diaphragm 1314 at a high speed, such as at a speed of at least about 10 mm / sec or at least about 40 mm / sec. The relatively rapid piercing of the top 1354 and / or the diaphragm 1314 by the biasing member 1397 can help prevent leakage of the contents of the chamber 1308, which may be under pressure through the piston 1316.

[0070] After the drug has been delivered to the user through needle 306, needle 306 may be automatically withdrawn from the user's body. Figure 12 to Figure 14 , the translation mechanism 1366 can be operated in a reverse mode such that the direction of rotation of the screw is opposite compared to the insertion step. This reverse rotation can move the piston 316 back toward the first end 1304 and also cause the vial 1302 to move in the opposite direction along the axis 40 (compared to during fluid delivery and insertion of the needle 306). The movement of the vial 1302 in the opposite direction can cause Fig.12 The ramp 1500 in the device (which is attached to the wall 1391) pushes against the ramp 243 of the stop 240. This can deflect the stop 240 about its fixed end 241 in the direction of arrow 240a and allow the shuttle 340 to move from its second position to its third position to retract the needle 306 as described above. In this way, both needle withdrawal and needle insertion into the patient can be accomplished with a single spring within the device.

[0071] It is further contemplated that the fluid conduit 300 can be the only fluid conduit of the auto-injector 2 that is configured to be in fluid communication with the vial 1302. Thus, during normal operation of the auto-injector 2, the drug from the vial 1302 can be deployed and enter the user's body only through the fluid conduit 300. In addition, the needle 306 can be the only needle of the auto-injector 2 that is configured to be deployed into the patient's body. In this way, a single piece of metal or plastic can be used to transport the fluid from the vial 1302 to the patient's body.

[0072] Sterile needle shield

[0073] refer to Fig.24 and Fig.25 , the autoinjector 2 may include a needle cover or needle shield 2400 configured to help maintain the sterility of the needle 306. The needle shield 2400 may extend from the first end 2402 toward the second end 2404. The flange 2406 may be disposed at the first end 2402, and the tubular extension 2408 may extend from the flange 2406 toward the second end 2404. The needle shield 2400 may include an opening 2410 through the flange 2406, which may be in communication with a lumen 2412 extending through the extension 2408. A seal 2414 may be disposed at the second end 2404 within the lumen 2412. The seal 2414 may define an opening 2416 that is in communication with the remainder of the lumen 2412. The seal 2414 may include a constriction portion 2414a, an intermediate portion 2414b, and an inner sealing portion 2414c. The middle portion 2414b may be disposed between the constriction portion 2414a and the inner sealing portion 2414c, and of the three components, the constriction portion 2414a may be disposed closest to the second end 2404. The middle portion 2414b may have a larger inner diameter than the constriction portion 2414a, and the constriction portion 2414a may have a larger inner diameter than the inner sealing region 2414c. The needle shield 2400 may also include a membrane 2418 covering the opening 2410 in the flange 2406. The membrane 2418 may be formed of a breathable material that is impermeable to liquids, such as, for example, a high-density polyethylene fiber membrane. In one example, the membrane 2418 may be The membrane 2418 can help keep the seal 2414 sterile so that when the needle shield 2400 is disengaged from the housing 3, the seal 2414 does not contaminate the needle 306.

[0074] The flange 2406 and the extension 2408 may be formed of plastic or other suitable materials, while the seal 2414 is formed of a rubber material. In another embodiment, the flange 2406 and the extension 2408 may also be formed of rubber. The rubber material may be substantially similar to the material forming the plug 1356a described above. For example, the rubber material forming the flange 2406, the extension 2408, and the seal 2414 may be permeable to a sterilant or a sterilizing gas (such as, for example, ethylene oxide or vaporized hydrogen peroxide). The rubber material may include one or more of isoprene, ethylene propylene diene monomer (M-grade) rubber (EPDM), styrene-butadiene, and a thermoplastic (TPE) elastomer, etc. In one embodiment, when the flange 2406 is formed of a rubber material permeable to a sterilant, the flange 2406 may not include the opening 2410, but may be a solid material plug.

[0075] The needle shield 2400 can be coupled to the auto-injector 2 to maintain the sterility of the needle 306 during transportation of the auto-injector 2, for example, before use. During this coupling, the needle 306 can pierce the inner sealing portion 2414c of the seal 2414 so that the seal 2414 forms a seal around the needle 306. That is, the inner sealing portion 2414c can initially be a closed and pierceable film. Alternatively, the inner sealing portion 2414c can be a constriction portion having an inner diameter smaller than the constriction portion 2414a, and the needle 306 can slide through this smaller constriction portion. The pierced portion (inner sealing portion 2414c) of the seal 2414 can be relatively thin so that it does not significantly blunt the needle 306. The constriction portion 2414a can engage with a portion of the intermediate segment 310 of the catheter 300 and form a seal around it. The intermediate segment 310 can have an outer diameter larger than the outer diameter of the needle 306. Additionally, a volume or gap 2414d may be formed between the inner diameter of the intermediate portion 2414b and the outer diameter of the intermediate segment 310 .

[0076] After the needle shield 2400 is coupled to the auto-injector 2, the auto-injector 2 can be sterilized by exposure to a sterilizing gas (e.g., ethylene oxide). The inner cavity 2412 and the gap 2414d, the surfaces defining the inner cavity 2412 and the gap 2414d, and the components contained therein (such as, for example, the exposed portion of the needle 306 that pierces through the tissue of the patient / user) can be sterilized after exposure to the sterilizing gas. The user may be instructed to manually remove the needle shield 2400, for example, by pulling the needle shield 2400 away from the housing 3. In another embodiment, the needle shield 2400 may be integrated with the packaging of the auto-injector 2 so that when the auto-injector 2 is removed from the packaging, the needle shield 2400 is removed from the auto-injector 2. For example, the flange 2406 may be fixed to the packaging (not shown) by an adhesive. Then, when the user withdraws the auto-injector 2 from the packaging, the needle shield 2400 will be disengaged from the housing 3 so that the needle 306 can be freely deployed in the normal operation of the auto-injector 2. In some cases, exposed portions of the seal 2414 that are closer to the second end 2404 than the constriction 2414a (and / or the constriction 2414a itself) may become contaminated after sterilization. Therefore, it may be important that these contaminated surfaces do not contact the needle 306 during withdrawal of the shield 2400 from the autoinjector 2. The narrower inner diameter of the inner seal portion 2414c helps ensure that these potentially contaminated portions do not contact the needle 306, particularly those portions of the needle 306 that are inserted into the tissue of the patient / user, by keeping the extension 2408 of the shield 2400 centered as the shield 2400 is removed.

[0077] In an alternative embodiment, the seal 2414 can be coupled directly to the driver 320. In this embodiment, the seal 2414 can seal against the plastic or other portion of the extension 2408, and the seal 2414 will remain within the auto-injector 2 when the needle shield 2400 is removed.

[0078] Electronic Devices

[0079] Figure 4A A control system 1400 of the automatic injector 2 is shown. The control system 1400 may include components located on a first electronic board 1402 and a second electronic board 1404, and may also include a power supply 1406. The first electronic board 1402 may include a controller 1408, an activation switch 1409, a touch sensor 1410, a needle insertion switch 1412, and a transmitter 1414. The second electronic board 1404 may include a detector 1416, an audio module 1418, a visual module 1420, and a tactile module 1422. One or more components of the first electronic board 1402 and the second electronic board 1404 can be operably coupled to the controller 1408 and powered by the power supply 1406. The controller 1408 can also be operably coupled to the translation mechanism 1366, and can be configured to control the operation of the translation mechanism 1366 to initiate and control needle insertion and retraction as set forth above. During the final assembly step in which the vial 1302 is inserted into the housing 3, the translation mechanism 1366 may be coupled to the first electronic board 1404 via one or more spring contacts.

[0080] Most of the assembly of the autoinjector 2 can be performed, for example, on an assembly line at a manufacturing facility. The two device halves (or portions) can then be transported to a drug filling or final assembly facility. In practice, the two separate parts 1490 and 1492 do not need to be the same size, as Figure 4BAs shown. Once a drug vial (e.g., vial 1302) is filled with a drug or other medicament, vial 1302 can be assembled with the rest of the auto-injector 2. For example, two device halves (portions 1490 and 1492) can be assembled with the drug vial 1302 filled therein. In one example, portion 1490 and translation mechanism 1366 can snap into place behind vial 1302. Portion 1490 can be a portion of housing 3 that includes a base or module configured to house translation mechanism 1366 and its associated electronics. Portion 1492 can be a portion of housing 3 that houses substantially all of the other components described herein, including, for example, the needle mechanism, sterile connector, and piercing mechanism described herein. In this example, electrical connection to the motor of the translation mechanism 1366 must be made during the snapping of the translation mechanism 1366 behind the vial 1302 (i.e., during the assembly step in which the parts 1490 and 1492 and the vial 1302 are combined to form a complete, functional auto-injector 2). To accommodate such electrical connection, the drive train of the translation mechanism 1366 may include one or more spring contacts 1494 (see FIG. Figure 4C ), the one or more spring contacts 1494 will contact the pads 1495 on the first electronic board 1402 when assembled (also refer to Figure 4C ). Thus, the connection between the translation mechanism 1366 and the first electronic board 1402 (including the controller 1408) can be made without any loose wires or other similar structures.

[0081] Such an assembly process may be relatively simpler than a device (eg, an automatic injector) having a relatively more complex final assembly process. Thus, the intended assembly process described herein may reduce labor costs.

[0082] The controller 1408 can be configured to receive information from the systems and system components described above and process the information according to various algorithms to generate control signals for controlling the translation mechanism 1366. The processor can receive information from the systems and system components, process the information according to various algorithms, and generate information signals that can be directed to, for example, an audio module 1418, a visual module 1420, a tactile module 1422, or other indicators of the second electronic board 1404 to inform the user of the system status, component status, process status, or any other useful information that the system is monitoring. The processor can be a digital IC processor, an analog processor, or any other suitable logic or control system that executes a control algorithm.

[0083] As mentioned above Figure 2 and Figure 3As discussed, the activation switch 1409 may be a mechanical plunger-type switch extending away from the tissue engagement surface 4 of the auto-injector 2. The activation switch 1409 may include a circuit that is disconnected unless the activation switch 1409 is pressed. For example, when the auto-injector 2 is attached to the user's skin, the switch 1409 may be pressed, thereby completing the circuit and indicating to the controller 1408 that the auto-injector 2 should be activated. In order to save power, the components of the auto-injector 2 may be in an idle or sleep mode until the switch 1409 is activated. In yet another example, the auto-injector 2 may not be powered at all before the activation of the switch 1409, and the deactivation of the switch 1409 may completely cut off the power supply to the auto-injector 2. Although a mechanical plunger-type switch is disclosed, any other suitable mechanism for activating the auto-injector 2 may be utilized, including, for example, a button pressed by a user, a voice signal, a wireless signal from another electronic device, and the like.

[0084] Touch sensor 1410 can be configured to help controller 1408 determine whether automatic injector 2 is correctly deployed on user's skin. In one example, touch sensor 1410 can be a capacitive sensing electrode or any other device, which is configured to distinguish contact with skin rather than contact with other materials (such as, for example, wood, plastic, metal or another material). When skin is near the capacitive sensing electrode, a signal indicating such contact can be sent to controller 1408. Therefore, even if switch 1409 is pressed, touch sensor 1410 can also be used to verify that automatic injector 2 is correctly placed on user's skin. Touch sensor 1410 can include a capacitive sensing electrode coupled to the first electronic board 1402 and also coupled to the inside of housing 3. Housing 3 and adhesive patch 12 can be used as a covering (insulator), which acts as a dielectric between user's skin and capacitive sensing electrode. The contact of the housing 3 near the capacitive sensing electrode and / or the part of adhesive patch 12 can increase the capacitance of the electrode, for example, by about 1pF to about 10pF, thereby indicating that automatic injector 2 is placed on the skin surface.

[0085] The needle insertion switch 1412 can be configured to send a signal to the controller 1408 that the needle 306 is deployed within the user. Fig.15, the needle insertion switch 1412 may include a curved cantilever 1510 including a first contact 1512. The needle insertion switch 1412 may also include a second contact 1514. When the needle 306 is deployed into the user, the first contact 1512 may be placed in electrical contact with the second contact 1514. During the deployment of the needle 306, the driver 320 may move downward along the axis 44 and deflect the curved cantilever 1510 and the first contact 1512 toward the second contact 1514. When the first contact 1512 and the second contact 1514 are connected to each other, a signal may be sent to the controller 1408 indicating that the needle 306 has been successfully deployed into the user. Separation of the first contact 1512 and the second contact 1514 may indicate that the needle 306 has been retracted from the user.

[0086] The emitter 1414 and the detector 1416 can operate as an optical interrupt sensor or photo interrupter to allow the controller 1408 to determine the state of the automatic injector 2. The emitter 1414 can be a light emitting diode (LED) or other suitable light emitter, and the detector 1416 can be, for example, a phototransistor configured to receive light emitted by the emitter 1414. In one example, the emitter 1414 can emit infrared light, but other suitable wavelengths of light can also be used. The use of infrared light can help reduce interference from external light. The emitter 1414 and the detector 1416 can be arranged relative to each other within the housing 3 so that the light beam 1430 can pass from the emitter 1414 through the vial 1302 to the detector 1416. The vial 1302 and any fluid contained therein can be at least partially transparent to the light beam 1430 so that the light beam 1430 can pass through the vial 1302 and its contents. When the piston 1316 moves toward the second end 1306 during drug delivery (reference Fig.13 and Fig.14 ), the piston 1316, and in particular the shoulder of the piston 1316, can interrupt the light beam 1430. When the detector 1416 fails to sense the light beam 1430, a signal can be sent to the controller 1408, which can interpret the signal to indicate the end of the injection (e.g., all the drug contained in the vial 1302 has been expelled). In some examples, the refraction path of the light beam 1430 can be taken into account when positioning the emitter 1414 and the detector 1416 relative to each other. For example, the light beam 1430 can be refracted as it passes through the vial 1302 and any liquid contained therein, and the emitter 1414 and the detector 1416 can be offset from each other accordingly. In addition, the emitter 1414 and the detector 1416 can be offset from the center of the housing 3 so that the shoulder of the piston 1316 can block the light beam 1430. In at least some examples, an optical interruption sensor or similar mechanism can help avoid false alarms in the event of a drive train failure. That is, the optical switch may help the controller 1408 determine that an injection is not complete with greater accuracy than other mechanisms.

[0087] The audio module 1418 may include a speaker or the like to provide audio feedback to the user. The opening in the housing 3 may facilitate the propagation of sound from the audio module 1418 to the user. The audio module 1418 may generate a tone or other sound at the beginning and end of the injection, and / or a tone or other sound indicating any other benchmark during the injection. The visual module 1420 may include one or more LEDs or similar devices to provide visual feedback to the user. The visual module 1420 may include LEDs of different colors to provide various messages to the user. For example, a plurality of green LEDs arranged in a ring may be used to display the progress of the injection over time, and a red LED may be used to display an error to the user. Any other suitable color, combination and / or number of LEDs may be used in various instances. For example, a combination of red, blue and purple LEDs may be utilized. In one arrangement, sixteen LEDs may be arranged in a circle having a diameter of about 26.5 mm or a diameter of about 10.0 mm to about 40.0 mm. The LEDs may be sequentially activated around the circle to indicate the progress of the injection (e.g., in a progress ring arranged in a manner similar to a clock - see, e.g. Figure 4C 52 in the progress ring). The controller 1408 may also be configured to receive feedback from various sensors and readjust the speed at which various LEDs are activated based on feedback from the sensors. For example, the LEDs in the progress ring may be activated in three or more operating stages (including, for example, the injection process startup stage, the injection stage, and the retraction stage). Those of ordinary skill in the art will recognize that the automatic injector 2 may have more or fewer operating stages than the three operating stages described above. There may be an expected time to complete each stage, but there may also be some variation in the actual time experienced during any of the aforementioned operating stages of the automatic injector 2. An algorithm may be used, for example, to help avoid premature activation of an LED when a certain stage ends earlier than expected, or to stop progress along the ring when a certain stage takes longer than expected. At any given moment, the algorithm may divide the remaining estimated time for completing drug delivery by the number of unactivated LEDs in the progress ring to determine the rate at which the remaining LEDs in the progress ring should be activated.

[0088] For example, prior to the injection sequence startup phase, the LEDs may be activated at a rate equal to the estimated time for the entire drug delivery process (e.g., the estimated time for the injection sequence startup phase, injection phase, and retraction phase to all be completed) divided by the total number of unactivated LEDs in the progress ring. In other words, the estimated time for the entire drug delivery process may be divided by a number that is the total number of LEDs in the progress ring minus the number of any already activated LEDs. Thus, for example, if one LED has already been activated, the estimated time for the entire drug delivery process may be divided by a number that is one less than the total number of LEDs in the progress ring.

[0089] After completing the injection sequence startup phase, the LEDs may be activated at a rate equal to the sum of the estimated times for completing the remaining phases (e.g., the injection phase and the retraction phase) divided by the number of unlit LEDs in the progress ring. After completing the injection phase, the LEDs may be activated at a rate equal to the estimated time to complete the retraction phase divided by the number of unlit LEDs.

[0090] The visual module 1420 may also include a display screen, a touch screen, or other suitable device to provide one-way or two-way communication with the user. The user can see the visual module 1420 from the outside of the housing 3 through a window in the housing 3. The tactile module 1422 may include, for example, a tactile motor configured to generate vibrations that can be felt by the user. The vibrations may indicate the start and end of the injection, and / or may help provide additional information to the user.

[0091] Controller 1408 can be coupled to a wireless communication module and an antenna. The wireless communication module can be configured to transmit data from controller 1408 to, for example, a mobile device, a computer, a cellular phone, etc. The wireless communication module can be configured to transmit information through one or more wireless modalities (such as, for example, Bluetooth, Bluetooth Low Energy (BLE), infrared, cellular networks, and wireless networks, etc.). The antenna can be any suitable device configured to assist the wireless communication module in data transmission and / or amplification. Therefore, controller 1408 can be configured to transmit diagnostic information of the user and / or the automatic injector 2, information related to the completion of the injection, and / or information related to the error state of the automatic injector 2 to the user's device or to the cloud. Signals indicating needle insertion and / or early device removal can also be transmitted through the wireless communication module. Controller 1408 can also receive start and / or delay commands through the wireless communication module.

[0092] Fig.16 An exemplary method 2000 according to the present disclosure is shown. The method 2000 may start at step 2002, where the user may position the automatic injector 2 on their body so that the tissue engagement surface 4 contacts the skin surface. The automatic injector 2 may be installed in any suitable position, such as, for example, thigh, abdomen, shoulder, forearm, upper arm, leg, buttocks or other suitable positions. The automatic injector 2 may be fixed to the skin by an adhesive patch 12. At step 2002, the fixation of the automatic injector 2 may cause the activation switch 1409 extending outward from the tissue engagement surface 4 to be depressed and complete the circuit. The completion of the circuit may cause a signal to be sent to the controller 1408 to switch from power saving, sleep mode to active mode. Alternatively, any other suitable mechanism may energize the automatic injector 2 or otherwise activate the automatic injector 2 before or after step 2002.

[0093] Once the auto-injector 2 is activated at step 2002, the method 2000 may proceed to step 2004, where the controller 1408 may determine whether the tissue engaging surface 4 is positioned on the skin surface. At step 2004, the controller 1408 may receive a measurement from the touch sensor 1410 indicating whether the auto-injector 2 is positioned on the skin or another surface. If the controller 1408 determines that the touch sensor 1410 is in contact with the skin, for example, when the capacitance value received from the touch sensor 1410 is within a predetermined range, the method 2000 may proceed to step 2008. If the controller 1408 determines that the touch sensor is not in contact with the skin, for example, if the capacitance measurement received from the touch sensor 1410 indicates that the auto-injector 2 is in contact with a non-skin surface such as wood or metal, the method 2000 may proceed to step 2006. At step 2006, the auto-injector 2 may be placed in an error state. In the error state, an LED (e.g., a red LED) may be activated to indicate to the user that an error has occurred, or a message may be displayed on a display screen. In some instances, the auto-injector 2 may require a manual reset before completing the injection. In other instances, the auto-injector 2 may loop back to step 2004, where the controller 1408 continuously attempts to determine whether the touch sensor 1410 is in contact with the skin. The method 2000 may also require that the touch sensor 1410 is in contact with the skin during the entire injection. Thus, if at any point during the injection, the controller 1408 determines that the touch sensor 1410 is no longer in contact with the skin, the controller 1408 may stop the injection (e.g., by stopping further movement of the translation mechanism 1366), may generate an error signal or message, and if the needle 306 has been extended, it may be retracted.

[0094] At step 2008, the controller 1408 may send a signal to activate the translation mechanism 1366. Once the translation mechanism 1366 is activated, it may move toward the second end 1306 of the vial 1302 (see FIG. Fig.13 and Fig.14 ), thereby moving the vial 1302 itself in the same direction. This can move the needle 308 in the opposite direction to access the vial 1302 as described above. The movement of the drive 1398 and the needle 308 causes the carriage 202 to move in the same direction, which describes the movement of the vial 1302 by Figures 5 to 11 The mechanism described in culminates in a chain of events that deploys the needle 306 into the user. The translation mechanism 1366 will continue to move toward the second end 1306 until the desired amount of the drug contained in the vial 1302 is dispensed into the user.

[0095] The method 2000 may proceed to step 2010, where the controller 1408 may determine whether the injection is complete. This determination may be based on the interruption of the beam 1430 by the piston 1316 (as shown in FIG. Figure 4A , Fig.13 and Fig.14 That is, when the light beam 1430 is disconnected (not received by the detector 1416), the controller 1408 can determine that the injection is complete. Once the controller 1408 determines that the injection is complete, the controller 1408 can send a signal to the translation mechanism 1366 to reverse the rotation direction of the screw, which can cause the ramp 1500 to push against the ramp 243 of the stopper 240, thereby retracting the needle 306 (as described above with reference to Fig.11 1302). In one example, the controller 1408 may establish a delay after receiving an indication that the light beam 1430 has been interrupted. The delay may be, for example, 0.1 seconds to 60 seconds. Additional end detection mechanisms may be used in place of or in combination with the interruption-type sensors described above. For example, the current of the motor of the translation mechanism 1366 may be used to determine whether the injection has been completed. That is, when the piston 1316 reaches the second end 1306 of the vial 1302, the current on the motor will increase (e.g., due to the piston 1316 engaging the end of the vial 1302), thereby indicating that all or substantially all of the contents of the vial 1302 have been expelled. An exemplary combination may include the use of the light beam 1430, wherein the interruption of the light beam 1430 indicates, for example, that 90% to 98% of the injection has been completed. The current of the motor of the translation mechanism 1366 may then be analyzed to determine whether the remaining 2% to 10% of the injection has been completed. In another example, instead of using an optical switch, the controller 1408 can use a delay from the initiation of the translation mechanism 1366 to determine when to reverse the translation mechanism 1366. In one example, this delay can be, for example, about 1 second to about 120 seconds, but other suitable times are also contemplated. In any case, the delay from the initiation can be long enough to allow the vial 1302 to be emptied.

[0096] In some instances, the time limit for the injection process measured from the initial activation of the activation switch 1409 to the retraction of the needle 306 from the user's body after the drug is delivered can be from about 20 seconds to about 90 seconds, or from about 25 seconds to about 60 seconds, from about 30 seconds to about 45 seconds, or less than or equal to about 120 seconds, or less than or equal to about 90 seconds, or less than or equal to about 60 seconds, or less than or equal to about 45 seconds, or less than or equal to about 30 seconds.

[0097] The method 2000 may also include additional steps. For example, the method 2000 may include determining whether the drug in the vial 1302 is too cold to be delivered to the user, whether the power source 1406 has sufficient energy to complete the injection, whether the needle 306 has been deployed and / or retracted prematurely, whether the current of the motor of the translation mechanism 1366 is within an appropriate range, and whether the injection process has been extended beyond a maximum acceptable process time. When the controller 1408 senses any of the above errors, it may communicate such errors to the user and end the ongoing injection by, for example, stopping or reversing the translation mechanism 1366 and retracting the needle 306 from the user.

[0098] Alternative Implementation

[0099] Figures 17 to 19 Another embodiment of a needle mechanism is shown. Needle mechanism 2400 includes a base 2402 and a shuttle 2420. Base 2402 may have an extension member 2404 extending away from the top surface of base 2402. Base 2402 may also include a groove 2406 extending along the longitudinal axis of base 2402 (parallel to axis 40) and recessed into the top surface of base 2402. Groove 2406 may extend through first wall 2407 and second wall 2408 of base 2402, and also extend through extension member 2404. Extension member 2404 may include, for example, a slot 2410 extending from the top of extension member 2404 through a portion of base 2402 toward the bottom surface of base 2402. Slot 2410 may be positioned generally perpendicular to groove 2406 and extend parallel to axis 44. Base 2402 may also include a pin 2412 and a second pin 2414.

[0100] The shuttle 2420 can include an end member 2422 coupled to a first wall 2426 on a first side and to a second wall 2428 on a second side. The first wall 2426 and the second wall 2428 can be substantially parallel to each other. The first wall 2426 and the second wall 2428 can be spaced apart a distance of the width of the base 2402 to allow the base 2402 to translate relative to the shuttle 2420. An opening 2424 can extend through the end member 2422, and it can be configured to receive a first end of the shaft 2456.

[0101] Wall 2426 may include a first slot 2430, a second slot 2432, and a driver member opening 2434 having an enlarged portion 2434a (wherein the protrusion 2454 may be in a first undeployed configuration). The first slot 2430 may be positioned adjacent to and longitudinally spaced from the second slot 2432. The first slot 2430 engages the pin 2412, and the second slot 2432 engages the pin 2414. The slots 2430, 2432 may include a first curved portion or injection ramp extending from the bottom of the shuttle 2420 toward the top, a top end positioned near the opening 2434, and a second curved portion or removal ramp extending from the top end to a position near the bottom of the shuttle 2420. When viewed from above the needle mechanism 2400, the first curved portion may have, for example, a convex shape, and the second curved portion may have, for example, a concave shape. The injection ramp may have, for example, an angle and curvature that is less than the angle and curvature of the removal ramp. The shallower injection bevel can provide a mechanical advantage when the part is stationary to help overcome static friction. The first curved portion allows a needle (e.g., needle 306 described above) to be inserted into the user's body for administration of the medicament, and the second curved portion allows the needle 306 to be removed from the user's body. The second wall 2428 may also include two slots and an opening similar to the slots 2430 and 2432 and the opening 2434. The slots and openings of the second wall 2428 may be arranged in a manner similar or identical to those positioned on the wall 2426.

[0102] The needle mechanism 2400 may further include a resilient member or spring (not shown) coupled to the shaft 2456. The shaft 2456 may be positioned in the opening 2424 of the shuttle 2420. The shaft 2456 may be coupled to the protrusion 2454. The protrusion 2454 may slide through the slot 2410 of the extension member 2404 and may be coupled to the needle 306.

[0103] In order to Fig.17 The undeployed configuration shown in the Fig.18 2430 and 2432, the longitudinal force applied to the shuttle 2420 also pushes the shuttle 2420 downward. This downward movement also moves the protrusion 2454 downward through the slot 2410, thereby deploying the needle 306. When the needle mechanism 2400 is in the deployed configuration, the pins 2412 and 2414 are positioned at the top or connection between the injection ramp and the removal ramp of the slot 2430 and the slot 2432. In addition, the protrusion 2454 is positioned near the middle or center of the opening 2434. The protrusion 2454 is also positioned near the middle of the slot 2410 between the top surface of the extension member 2404 and the bottom of the slot 2410. The shaft 2456 can extend from the opening 2424 beyond the end of the shuttle 2420.

[0104] Once the medicament has been administered, the injection needle 470 can be removed by allowing the spring to further expand. The further expansion of the spring causes the shuttle 2420 to slide further longitudinally relative to the shaft 2456 along the longitudinal axis 40. Due to the curvature of the slots 2430 and 2432, the additional longitudinal force applied to the shuttle 2420 also pushes the shuttle 2420 upward. This upward movement also causes the protrusion 2454 to move upward through the slot 2410, thereby retracting the needle 306. The protrusion 2454 can be positioned in the drive member opening 2434 at the end closest to the end surface 2422. In addition, the protrusion 2454 is positioned near the top of the slot 2410. The shaft 2456 can extend further from the opening 2424 beyond the end of the shuttle 2420.

[0105] Another embodiment of the needle assembly is as follows Fig. 20As shown. Needle assembly 3300 includes: a bracket 3302, a driver 3320, a shuttle 3340, a gear 3360 and a spring (elastic member) 3370. Driver 3320 can be coupled to a fluid conduit (such as fluid conduit 300 described above) and can be configured to drive the needle into the user's body at the end of this fluid conduit. Driver 3320 can be similar to driver 320, except that driver 320 can only include one rack gear 3222 configured to be driven by gear 3360. Shuttle 3340 can be similar to shuttle 340, except that it can include a first rack gear 3342 and a second rack gear 3344. The first rack gear 3342 and the second rack gear 3344 can be longitudinally spaced apart but substantially parallel to each other, and can engage gear gear 3360 at different times. In some examples, the first rack gear 3342 and the second rack gear 3344 can be configured to engage gear gear 3360 only at different times. When the shuttle 3340 moves in the direction 3380 along the longitudinal axis 40, the second rack 3344 can rotate the gear 3360 in a first direction (e.g., counterclockwise), and when the shuttle 3340 moves in the direction 3380, the first rack 3342 can move the gear 3360 in a second direction (e.g., clockwise) opposite to the first direction. Rotation of the gear 3360 in the first direction can cause the driver 3320 to move downward through the rack 3222 and push the needle into the user's body, and rotation of the gear 3360 in the second direction can cause the driver 3320 to move upward to retract the needle from the user's body. Extension of the spring 3370, which can be coupled to the interior surface of the bracket 3302 and the shuttle 3340, can cause the shuttle 3340 to move in the direction 3380 to initiate deployment and subsequent retraction of the needle. In addition, it is contemplated that a stop similar to stop 240 may be used to impede longitudinal movement of shuttle 3340 when driver 3320 (and associated needle) is in the deployed configuration. The stop may then be moved out of the path of shuttle 3340 to allow driver 3320 and its associated needle to be retracted.

[0106] Yet another embodiment of the needle assembly is Fig.21 . Needle assembly 4000 includes carriage 4202 and a driver (shown only by protrusion 330). Needle assembly 4000 may also include the following components not shown, but which may be substantially similar to the components described above with the same names, such as, for example, a shuttle, deployment gears and retraction gears, and a spring. The driver of needle assembly 4000 may be coupled to a fluid conduit (such as fluid conduit 300) and may be configured to drive the needle into the user's body at the end of that fluid conduit. In an undeployed configuration (such as Fig.214600 ), the protrusion 330 of the driver may be blocked by the obstacle 4600. The carriage 4202 may be pushed in the direction 4002 to enable the protrusion 330 to slide down the ramp 4602, thereby moving the driver and the associated needle from the retracted configuration to the deployed configuration. The carriage 4202 may be pushed in the direction 4002 by, for example, the translation mechanism 1366 and the vial 1302 in a manner substantially similar to that described above with reference to the carriage 202.

[0107] Needle assembly 4000 may include a stopper 4240 that is separate from bracket 4202. Stopper 4240 may be urged in direction 4004 by spring 4241. One end of stopper 4240 may include an overhang 4242 that may help maintain the driver in the deployed configuration by blocking the retraction path of protrusion 330. Thus, when the driver is deployed, protrusion 330 may be positioned below overhang 4242 of stopper 4240, thereby preventing the driver from retracting until stopper 4240 is moved. Retraction of the driver and needle may be achieved by, for example, reversing the motor of translation mechanism 1366, which may apply a force in direction 4002 to stopper 4240 to compress spring 4241 via one or more mechanical linkages (not shown). Movement of stopper 4240 in direction 4002 may provide clearance for protrusion 330 to move back to the retracted configuration.

[0108] Yet another embodiment of the needle assembly is Fig. 22 and Fig.23 5300 includes a carrier 5302. In this embodiment, the stop 5240 can be configured to directly impede the rotation of the deployment and / or retraction gear 5360, rather than directly impeding the shuttle or driver of the needle assembly. In this embodiment, the gear 5360 can be coupled to a toggle 5362 via an axis 5361. The gear 5360 can rotate about an axis 5364 to facilitate deployment and / or retraction of an associated driver and / or needle. The toggle 5362 can have a length extending substantially perpendicular to the axis 5364 and can also rotate about the axis 5364.

[0109] The stopper 5240 may include an opening 5380 through which the toggle 5362 may be disposed. The opening 5380 may include a circular portion 5382 and a limiting portion 5384. The diameter of the circular portion 5382 may be greater than the length of the toggle 5362 so that the toggle 5362 (and the gear 5360) can rotate unimpeded while the toggle 5362 is disposed within the circular portion 5382. The stopper 5240 may be capable of sliding relative to the bracket 5302 by any suitable mechanism. When the stopper 5240 and the bracket 5302 slide relative to each other, the toggle 5362 may slide within the limiting portion 5384, which may be sized to limit the rotation of the toggle 5362 (and the gear 5360). For example, when the toggle 5362 is generally rectangular as shown, the limiting portion 5384 may also be rectangular.

[0110] It is noteworthy that the reference to "one embodiment" or "embodiment" herein means that the specific features, structures or characteristics described in conjunction with the embodiment may be included, adopted and / or incorporated in one, some or all embodiments of the present disclosure. The usage or appearance of the phrase "in one embodiment" or "in another embodiment" in this specification does not refer to the same embodiment, nor does it necessarily exclude one or more other embodiments. Individual embodiments or alternative embodiments are not limited to a single exclusive embodiment. The same applies to the terms "implementation" and "example". The present disclosure is not limited to any single aspect or embodiment thereof, nor is it limited to any combination and / or arrangement of such aspects and / or embodiments. In addition, each aspect of the present disclosure and / or its embodiments may be used alone or in combination with one or more other aspects of the present disclosure and / or its embodiments. For the sake of brevity, certain arrangements and combinations are not discussed and / or described separately herein.

[0111] Additionally, as noted above, an embodiment or implementation described herein as “exemplary” should not be construed as preferred or advantageous, for example, over other embodiments or implementations; rather, it is intended to convey or indicate that one or more embodiments are “exemplary” embodiments.

Claims

1. An injection device, comprising: A housing having an opening, a container disposed within the housing; a fluid conduit having a movable piercing end, the movable piercing end having a first configuration in which the fluid conduit is completely contained within the housing, and a second configuration in which the movable piercing end of the fluid conduit extends through the opening and to an exterior of the housing; and a shield removably coupled to the housing, the shield covering the opening when connected to the housing, the shield being configured to receive the piercing end of the fluid conduit when the fluid conduit is in the first configuration, and wherein the shield must be removed from the syringe to enable the fluid conduit to be moved from the first configuration to the second configuration.

2. The injection device of claim 1, wherein the shield comprises a material permeable to gaseous sterilants.

Images